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Summary
Cis-p lat inum or  c is-d iammine-dichloro-p lat inurn (CDDP),  a com-
pound of  p lat inum, has ant ineoplast ic  act iv i ty .  An i rnpor tant  s ide-
effect of CDDP is its nephroroxiciry.
In chapter 1 the purpose t-rf this thesis is formulated. An answer
was sought to questions about incidence, character and prevention of
CDDP-induced nephrotoxicity. The investigations were perforrned
in pat ients wi th d isseminated test icu lar  cancer.  Al l  pat ients were
treated s in-r i lar ly .  This  r reatment  consisted of  i r  remiss ion- induct ion
phase of 1+ courses. In each course of 3 weeks CDDP in a dosage of
20 mg/m) '* 'as adminis tered on each of  5 consecut ive days.  This
regimen also included vinblastine irnd bleomycin, drugs clf which no
nephrotoxicity has been reported. This remission-induction phase
was followed by a maintenance therapy during one year, in which
CDDP was given once every 6 weeks in a dosage oí 50 mg/m2.
In chapter 2 a revierv of the l iterature about CDDP-induced ne-
phrotox ic i ty  is  g iven.  In  the in i t ia l  phase of  exper imenta l  acute renal
failure a fall in renal plasma flow (RPF) occurred, usually accom-
panied by a reduct ion in  g lomerular  f i l t ra t ion rate (GFR).  In  animals
CDDP caused disturbances in renal function and morphologically
tubulo-interstit ial changes. The nephrotoxicity was dose related, ics
reversibil iry remained unclear. Reports on human nephrotoxicity are
without conformity. Our observations obtained at various moments
of treatment only partly agree with the experience of other authors.
Finally, rneasures to prevent nephrotoxicity are discussed.
In chapter 3 renal function is evaluated in 24 patients during the
remission-induction phase. GFR, effective renal plasma flow
(ERPF),  serum concentrat ion of  creat in ine and beta-2-microglobul in
were determined.  At  the end of  the remiss ion- induct ion phase me-
dian GFR and ERPF both were reduced 2317c tp < 0.01) .  A nephro-
toxic effect, hemodynarnically induced and acting directly on rhe
glomerular tuft is postulated on grounds of rhe relative change in
ERPF and absolute change in f i l t ra t ion f ract ion 1FF:  GFR/ERPF)
cclmpared to pretreatment values. The reduction in GFR and ERPF
remained unal tered in  the 6 weeks af ter  the remiss ion- induct ion
therapy.  Serum creat in ine and beta-2-microglobul in  however d id not
rise. It is suggested that under the influence of chemotherapy with
t0
CDDP the production of creatinine and beta-2-microglobuiin is
decreased.  Thus,  serum creat in ine and beta-2-microglobul in  are un-
suitable as parameters for renal function.
Chapter 4 deals with the course in renal function before and afrer
the remiss ion- induct ion and maintenance therapy in  9 pat ients.  The
median GFR decreased during the rernission-induction therapy frclm
L46 to 118 ml /min.  Dur ing the maintenance therapy no change in
median GFR was found. It is concluded that neither cumulation nor
reversibil i ty in nephrotoxicity occurred. The median ERPF decreased
over the tota l  observat ion per iod f rom 705 to I  l4  ml /min.  Median FF
and serum creatinine were not changed significantly. It is suggesred
that intrarenal hernodynamic changes play a role in the nephrotoxi-
city of CDDP.
In chapter  5 the course in  renal  funct ion in  8 pat ients dur ing thera-
py and I  year  af ter  i ts  terminat ion is  descr ibed.  The median GFR
decreased in comparison with the pretreatment value 15.5% at the
star t  o f  the maintenance therapy,  23( Í  ar  rhe end of  the maintenance
therapy and 15.5 7c one year  af ter  terminat ion of  therapy.  The com-
parable reduct ion in  ERPF at  those instants was 15.) ,  19 and 23.5%,
respect ive ly .  Indicat ions for  cumulat ive nephrotox ic i ty  dur ing the-
rapy or  improvement  of  renal  funct ion one year  af ter  t reatment  were
not  found.  Serum levels of  creat in ine and beta-2-rn icrogbbul in  d id
not express the changes in renal function.
Finally, in chapter 6 some concluding remarks about the quesrions
posed in the first chapter are made and an outl ine for future research
is given.
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